Avesthagen Limited, India’s leading knowledge based Life Sciences Company today announced its new Strategic Scientific Advisory Board concluded its first three-day meeting to evaluate and guide the company's scientific and research initiatives. The scientific review was done for all the four SBUs, bioNutrition, bioPharma, bioAgri and Science & Innovation of the company.

The advisory board consists of world renowned international scientists like, Dr Robert L Strausberg, Deputy Director-J Craig Venter Institute, Dr Jean-Pierre Isal (MD), Dr Chris Bowler, Organismes Photosynthetiques et Enviroment-Department de Biologie, Paris, Dr. Jean Luc Tonneau, Strategic Planning Director-Danone Research, Dr. Sven Thormahlen, Director General –Danone Research, Professor Jacques Henry Weil, Institute de Botanique, France, Prof. Frank Ganon, Director General -Science Foundation Ireland and Dr. Rita Colwell, Distinguished University Professor- University of Maryland

The national experts included Prof G Padmanabhan, Honorary Professor – Indian Institute of Science, Bangalore, Prof. N K Ganguly , Former Director General-Indian Council of Medical Research, India, Prof. Satyajit Mayor, Professor-Cellular Organization and Signaling Group, National Center for Biological Science, Bangalore.

Avesthagen has a bioPharma, bioNutra, biAgric products pipeline and has initiated two new projects, The Avestagenome Project – that will lead to development of novel biomarkers for healthcare management and a Cancer Stem Cells project.

Dr. Villoo Morawala-Patell, Founder & CMD, Avesthagen Limited, said, "We are honored that the esteemed board members have accepted our invitation and joined the Stragetgic Scientific Advisory Board of the company; we will look up to them for constant feedback and direction. Early validation by external thought leaders of our ideas and inventions on scientific value and significance will considerably increase the success rate of our biomedical innovations.”

- End -

AVESTHAGEN LIMITED (www.avesthagen.com) is India’s leading integrated systems biology platform company that focuses on achieving convergence of food, pharma and population genetics leading to predictive preventive and personalized healthcare. It employs 650+ people worldwide and is headquartered in Bangalore. Avesthagen Limited has established world class, state-of-the-art laboratory facilities in Bangalore. It began business operations in 2001.Since its inception Avesthagen has grown into one of India's leading healthcare technology group in India, and its activities include, in addition to its agri-biotechnologies product pipeline, development of clinically validated botanical bioActives, derived from Indian medicinal plants, as well as the development of a pipeline of bio-similar drugs. Avesthagen Limited has four strategic business units: bioPharmaceuticals, bioNutrition, bioAgriculture and Science & Innovation. Its partners include multiple top 10 global companies in each of its fields of research. Avesthagen Limited collaborates at every stage in the value chain with appropriate partners, both public and private, for access to and exchange of technology and overall commercial expertise to leverage the ‘India advantage’.

Disclaimer

Avesthagen Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, a public issue of its equity shares and to file a Draft Red Herring Prospectus with SEBI. This announcement does not constitute an offer of equity shares for sale in any jurisdiction, including the United States of America, and any equity shares of the Company may not be offered or sold in the United States absent registration under the United States Securities Act of 1933, as amended, or pursuant to an exemption from registratio.